The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Moving beyond the current SOC for AML
The current standard of care for acute myeloid leukemia (AML), which includes chemotherapy regimens such as the 7+3 regimen and stem cell transplants, may not be suitable for elderly patients, who constitute a majority of patients with AML. Alexandre Bazinet, MD, McGill University, Montreal, Canada, describes novel, lower intensity approaches towards treating AML, including 5-azacytidine and venetoclax. Dr Bazinet additionally mentions targeted inhibitors such as FLT3 and IDH1 inhibitors, as well as combinations of the aforementioned treatments to create new regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
